- About us
- Join Putnam
A company was approaching the European market with evidence from a placebo-controlled RCT, but with several established competitors in these markets comparative effectiveness evidence against competitors was required to support HTA activities.
Through our feasibility assessment, we reviewed the outputs of a systematic literature review to determine what analyses could be carried out to generate robust, indirect evidence of comparative effectiveness. A network-meta analysis (NMA) was deemed feasible (these analyses utilize common comparator arms across RCTs to generate results commonly accepted by HTA bodies).
We executed on the recommended analyses and delivered comparative effectiveness results which were used to support economic modelling and related HTA submissions in England. Our analyses were accepted by the UK HTA body (NICE) and formed a key component of our client’s successful NICE submission.
We carried out adaptations and sensitivity analyses to meet the needs of other markets including Germany, Ireland, and Portugal. Our follow up analyses formed a key part of subsequent HTA submissions, and we are currently developing a manuscript reporting the findings.